世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037978

低分子イノベーターAPI CDMO市場-規模、シェア、動向分析レポート、およびセグメント予測、2024〜2030

Grand View Research Inc.

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030

発刊日 2024/04

言語英語

体裁PDF/241ページ

ライセンス/価格241ページ

0000037978

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

低分子イノベーターAPI CDMOの市場規模、シェア、動向分析レポート:ステージタイプ別 (前臨床、臨床、商業)、顧客タイプ別、治療領域別、地域別、セグメント別予測、2024〜2030

市場規模と動向

低分子イノベーターAPI CDMOの世界市場の規模は、2023年に299億4,000万ドルと推定され、2024年から2030年にかけて6.53%のCAGRで成長すると予想されます。市場の成長要因には、低分子医薬品の需要の増加、製薬会社によるアウトソーシングの増加、臨床試験数の増加があります。さらに、新しい低分子イノベーターの原薬 (API) の開発を推進するための医薬品研究開発投資の増加、新しい治療法に対する需要の増加、がんや加齢性疾患の有病率の増加などが市場の重要な成長要因となっています。低分子は、世界的に新しい治療法の開発において重要な役割を果たし続けています。2023年、米国FDAは55の新薬を承認し、前年の37の承認から約50%の急増を記録しました。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Demand for Small Molecule Drugs
3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
3.2.1.3. Surge in Number of Clinical Trials
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios in Developing Economies
3.3. Technology Landscape
3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
3.3.1.1. Current Dynamics and Future Trends
3.3.1.1.1. Drug Discovery and Design
3.3.1.1.2. AI-Assisted Drug API Synthesis
3.3.1.1.3. Process Optimization
3.3.1.1.4. Supply Chain Management
3.3.1.1.5. Clinical Trial Optimization
3.3.1.1.6. Regulatory Compliance
3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
3.7. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.2. Phase I
4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.3. Phase II
4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.4. Phase III
4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Commercial
4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
5.3.1. Pharmaceutical
5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.2. Small
5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.3. Medium
5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.4. Large
5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Biotechnology
5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.2. Small
5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.3. Medium
5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.4. Large
5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Cardiovascular Diseases
6.1.2. Oncology
6.1.3. Respiratory Disorders
6.1.4. Neurology
6.1.5. Metabolic Disorders
6.1.6. Infectious Diseases
6.1.7. Others
6.2. Therapeutic Area Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.5.1. Cardiovascular Diseases
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Oncology
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Respiratory Disorders
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Neurology
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Metabolic Disorders
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Infectious Diseases
6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Others
6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. Japan
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.8. Taiwan
7.6.8.1. Key Country Dynamics
7.6.8.2. Competitive Scenario
7.6.8.3. Regulatory Scenario
7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.6. Israel
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Scenario
7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.4. Company Profiles
8.4.1. Strategy Mapping
8.4.2. Expansion
8.4.3. Partnerships
8.4.4. Acquisitions
8.5. Vendor Landscape
8.5.1. Key company market share analysis, 2023
8.5.2. Lonza Group Ltd.
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product/service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Novo Holdings (Catalent, Inc.)
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product/service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Thermo Fisher Scientific, Inc.
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product/service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Siegfried Holding AG
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product/service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Recipharm AB
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product/service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. CordenPharma International
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product/service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Samsung Biologics
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product/service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Labcorp
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product/service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Ajinomoto Bio-Pharma Services
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product/service benchmarking
8.5.10.4. Strategic initiatives
8.5.11. Piramal Pharma Solutions
8.5.11.1. Company overview
8.5.11.2. Financial performance
8.5.11.3. Product/service benchmarking
8.5.11.4. Strategic initiatives
8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
8.5.12.1. Company overview
8.5.12.2. Financial performance
8.5.12.3. Product/service benchmarking
8.5.12.4. Strategic initiatives
8.5.13. WuXi AppTec Co., Ltd.
8.5.13.1. Company overview
8.5.13.2. Financial performance
8.5.13.3. Product/service benchmarking
8.5.13.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 4 North America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 5 North America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 6 U.S. Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 7 U.S. Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 8 U.S. Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 9 Canada Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 10 Canada Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 11 Canada Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 12 Europe Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 13 Europe Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 14 Europe Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 15 Europe Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 16 UK Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 17 UK Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 18 UK Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 19 Germany Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 20 Germany Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 21 Germany Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 22 France Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 23 France Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 24 France Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 25 Italy Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 26 Italy Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 27 Italy Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 28 Spain Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 29 Spain Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 30 Spain Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 31 Denmark Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 32 Denmark Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 33 Denmark Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 34 Sweden Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 35 Sweden Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 36 Sweden Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 37 Norway Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 38 Norway Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 39 Norway Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 44 China Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 45 China Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 46 China Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 47 Japan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 48 Japan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 49 Japan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 50 India Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 51 India Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 52 India Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 53 Australia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 54 Australia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 55 Australia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 56 South Korea Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 57 South Korea Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 58 South Korea Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 59 Thailand Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 60 Thailand Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 61 Thailand Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 62 Taiwan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 63 Taiwan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 64 Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 65 Latin America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 67 Latin America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 68 Latin America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 69 Brazil Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 70 Brazil Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 71 Brazil Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 72 Mexico Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 73 Mexico Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 74 Mexico Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 75 Argentina Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 76 Argentina Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 77 Argentina Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 78 MEA Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 79 MEA Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 80 MEA Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 81 MEA Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 82 South Africa Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 83 South Africa Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 84 South Africa Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 88 UAE Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 89 UAE Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 90 UAE Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 91 Kuwait Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 92 Kuwait Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 94 Israel Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 95 Israel Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 96 Israel Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Small molecule innovator API CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2023(USD Million)
Fig. 16 Ancillary market outlook, 2023 (USD Million)
Fig. 17 Small molecule innovator API CDMO market dynamics
Fig. 18 FDA’s novel drug approvals in 2023
Fig. 19 Percentage of clinical trials by major countries in North America
Fig. 20 Percentage of clinical trials by major countries in Europe
Fig. 21 Percentage of clinical trials by major countries in Asia Pacific
Fig. 22 Percentage of clinical trials by major countries in Latin America
Fig. 23 Percentage of clinical trials by major countries in Middle East & Africa
Fig. 24 Porter’s five forces analysis
Fig. 25 Small molecule innovator API CDMO market: PESTEL analysis
Fig. 26 Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
Fig. 27 Small molecule innovator API CDMO market: Stage type movement analysis
Fig. 28 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Small molecule innovator API CDMO market: Customer type outlook and key takeaways
Fig. 35 Small molecule innovator API CDMO market: Customer type movement analysis
Fig. 36 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Large biotechnology customer in small molecule molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
Fig. 45 Small molecule innovator API CDMO market: Therapeutic area movement analysis
Fig. 46 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Regional market: Key takeaways
Fig. 54 Regional outlook, 2023 & 2030
Fig. 55 Regional outlook, 2023 & 2030
Fig. 56 North America small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 U.S. small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Canada small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 UK small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Germany small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 France small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Italy small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Spain small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Denmark small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Sweden small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Norway small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 MEA small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 South Africa small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Saudi Arabia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Clinical trial authorization process UAE
Fig. 86 UAE small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Regulatory framework: South Africa
Fig. 89 Kuwait small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Israel small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Asia Pacific small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 China small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 Regulatory bodies in India involved in pharmaceutical regulations
Fig. 98 India small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 Clinical trial authorization process in Japan
Fig. 101 Clinical research of medical products in Japan
Fig. 102 Japan small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Australia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Key country dynamics
Fig. 106 Clinical trial approval process in South Korea
Fig. 107 South Korea small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 Key country dynamics
Fig. 109 Thailand small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Taiwan small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Rest of APAC small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Key country dynamics
Fig. 114 Brazil small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 Key country dynamics
Fig. 116 Mexico small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 117 Key country dynamics
Fig. 118 Argentina pharmaceuticals registration details
Fig. 119 Argentina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 120 Market participant categorization
Fig. 121 Heat map analysis
Fig. 122 Market participant categorization

この商品のレポートナンバー

0000037978

TOP